Antisense Therapeutics Limited - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Antisense Therapeutics Limited - Product Pipeline Review - 2014" provides data on the Antisense Therapeutics Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Antisense Therapeutics Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Antisense Therapeutics Limited and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Antisense Therapeutics Limited - Brief Antisense Therapeutics Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Antisense Therapeutics Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Antisense Therapeutics Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Antisense Therapeutics Limited's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Antisense Therapeutics Limited's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Antisense Therapeutics Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Antisense Therapeutics Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Antisense Therapeutics Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Antisense Therapeutics Limited and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Antisense Therapeutics Limited Snapshot 4
Antisense Therapeutics Limited Overview 4
Key Information 4
Key Facts 4
Antisense Therapeutics Limited - Research and Development Overview 5
Key Therapeutic Areas 5
Antisense Therapeutics Limited - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Antisense Therapeutics Limited - Pipeline Products Glance 9
Antisense Therapeutics Limited - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Antisense Therapeutics Limited - Early Stage Pipeline Products 11
IND/CTA Filed Products/Combination Treatment Modalities 11
Preclinical Products/Combination Treatment Modalities 12
Antisense Therapeutics Limited - Drug Profiles 13
ATL-1102 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
ATL-1103 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
ATL-1101 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Antisense Therapeutics Limited - Pipeline Analysis 18
Antisense Therapeutics Limited - Pipeline Products by Therapeutic Class 18
Antisense Therapeutics Limited - Pipeline Products by Target 20
Antisense Therapeutics Limited - Pipeline Products by Route of Administration 21
Antisense Therapeutics Limited - Pipeline Products by Molecule Type 22
Antisense Therapeutics Limited - Pipeline Products by Mechanism of Action 23
Antisense Therapeutics Limited - Recent Pipeline Updates 24
Antisense Therapeutics Limited - Discontinued Pipeline Products 32
Discontinued Pipeline Product Profiles 32
ATL-1101 32
Antisense Therapeutics Limited - Company Statement 33
Antisense Therapeutics Limited - Locations And Subsidiaries 34
Head Office 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables
Antisense Therapeutics Limited, Key Information 4
Antisense Therapeutics Limited, Key Facts 4
Antisense Therapeutics Limited - Pipeline by Indication, 2014 6
Antisense Therapeutics Limited - Pipeline by Stage of Development, 2014 7
Antisense Therapeutics Limited - Monotherapy Products in Pipeline, 2014 8
Antisense Therapeutics Limited - Phase II, 2014 9
Antisense Therapeutics Limited - Phase I, 2014 10
Antisense Therapeutics Limited - IND/CTA Filed, 2014 11
Antisense Therapeutics Limited - Preclinical, 2014 12
Antisense Therapeutics Limited - Pipeline by Therapeutic Class, 2014 19
Antisense Therapeutics Limited - Pipeline by Target, 2014 20
Antisense Therapeutics Limited - Pipeline by Route of Administration, 2014 21
Antisense Therapeutics Limited - Pipeline by Molecule Type, 2014 22
Antisense Therapeutics Limited - Pipeline Products by Mechanism of Action, 2014 23
Antisense Therapeutics Limited - Recent Pipeline Updates, 2014 24
Antisense Therapeutics Limited - Discontinued Pipeline Products, 2014 32